Introduction
Acute coronary syndrome (ACS) is still one of the most common cardiac diseases, with substantial morbidity and mortality. 1 The clinical spectrum of ACS includes unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. Worldwide each year more than 7 million people experience
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Degli esposti et al acute myocardial infarction (AMI), in which 1-year mortality rates are now 10%, but vary with patient characteristics. [2] [3] [4] Current guidelines for the management of ACS recommend both a pharmacological approach and a mechanical reperfusion with percutaneous coronary intervention (PCI). [5] [6] [7] Antiplatelet agents are the mainstay therapy for all clinical settings of ACS. 8 Given that platelet-rich thrombi are a common feature of all forms of ACS, antiplatelet therapies are indicated both in the acute phase of ACS and in the postacute phase to reduce the risk of reinfarction.
In particular, dual antiplatelet therapy (DAPT) has become the standard of care for patients with AMI, and new antiplatelet agents have become available. 9 European guidelines currently recommend treatment with the initiation of DAPT with acetylsalicylic acid and an irreversible thienopyridine P2Y 12 inhibitor (clopidogrel or prasugrel) or reversibly binding (ticagrelor) to reduce the risk of acute ischemic complications and recurrent atherothrombotic events for up to 1 year after ACS. 5 Notably, despite progress in evidence-based treatments and improved outcomes, preventive care post-ACS remains suboptimal, thus resulting in worse outcomes and higher health care costs. 10 Among patients who survive an AMI, 20% suffer a second cardiovascular (CV) event in the first year and approximately 50% of major coronary events occur in those with a previous hospital discharge diagnosis of AMI. 11 Within the first year after AMI, CV rehospitalizations are common. [12] [13] [14] Although the total allcause rehospitalizations cannot be prevented, readmissions within a short time can be reduced with a proper prevention and they can be considered as a marker for low-quality care and efficiency. 15 Several studies have reported 30-day rehospitalization rates and predictors of composite events (such as major adverse cardiac events) among patients surviving hospitalization for AMI; [16] [17] [18] [19] nevertheless, few studies have evaluated the residual risk of recurrent events after treatment with DAPT, including both all-cause mortality rate and potential predictors of death. In addition, there are few contemporary data that describe the economic impact among patients surviving an AMI after treatment with DAPT. Health care costs related to disease morbidity are most closely associated to the prevention and management of disease directly. Additionally, in a rapidly aging society, the number of AMI patients with higher severity is likely to increase, which can lead to an increase in medical expenditures related to hospitalization.
This study aims to assess all-cause mortality and CV events in patients after 12 months of treatment with DAPT after hospitalization for AMI in a unselected Italian population under clinical practice setting. Health care direct costs (in terms of pharmaceutical and hospitalization costs) for the management of patients' post-AMI will be assessed as well.
Methods

Data sources
This study was based on data from the administrative databases of six Italian local health units (LHUs), geographically distributed. In particular, the following databases were used: the Health-Assisted Subjects' Database, containing patients' demographic data; Outpatients and Inpatients Pharmaceutical Drugs Database, providing information for each medication prescription, such as the ATC (Anatomical Therapeutic Chemical) code of the drug purchased, the number of packages, the number of units per package, the dosages, the unit cost per package, and the prescription date; Hospital Discharge Database, which includes all hospitalization data with the discharge diagnosis codes classified according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). This administrative database is complete and includes validated data, and it has been used in previous real-world studies. 20, 21 The patient code in each database permitted electronic linkage between all databases. Informed consent is not required by the LHU ethics committee for using the encrypted retrospective information, according to Italian regulations. This study was notified to the local ethics committee in each participating LHU according to the Italian law, 22 regarding the conduct of observational analysis, and the LHU Ethics Committees approved the study.
Study design and cohort definition
This observational retrospective cohort analysis included all beneficiaries of each LHUs hospitalized with a primary diagnosis of AMI (ICD-9-CM code: 410) between January 1, 2010, and December 31, 2011 (enrollment period). The date of AMI discharge was identified as the index date (ID), which represents the enrollment day of each individual patient, who was then followed for 36 months from ID (follow-up period). Data on baseline characteristics, including demographics, risk factors, and medical history, were investigated for 12 months prior to ID (characterization period). Only cohort of patients hospitalized with a primary diagnosis of AMI during the enrollment period and exposed to a period of treatment with DAPT after AMI discharge of 12 months [acetylsalicylic acid (ATC code: B01AC06)+P2Y12 adenosine diphosphate receptor inhibitors (ATC codes: B01AC04, B01AC05, B01AC22, B01AC24)] was considered for the first and second objectives in the analysis. All-cause mortality and CV hospitalizations occurring from the end of treatment The presence of chronic kidney disease was also identified by ICD-9-CM code: 585 (primary or secondary discharge reasons) during the characterization period.
Hospitalizations for AMI and all-cause mortality occurring from the end of treatment with DAPT to the subsequent 36-month follow-up period were considered.
A patient was defined in treatment with antidiabetic, antihypertensive, or agent for heart disease if he had at least two prescriptions of oral hypoglycemic drugs and/or insulin (ATC code: A10), antihypertensive drugs (ATC codes: C02, C03, C08), or cardiac drugs (ATC code: C01), respectively, during the follow-up period. A patient was defined as treated with statins (ATC code: C10AA, C10BA02), beta-blocking agents (ATC code: C07), or angiotensin-converting enzyme (ACE)-inhibitors/angiotensin II receptor antagonists (AAIIs) (ATC code: C09) if he had at least two prescriptions of such drugs during the follow-up period. Hospitalizations with cancer diagnosis and blood transfusion [ICD-9-CM code (primary or secondary discharge reasons): 9.90] required during the follow-up period were also considered.
cost analysis
The average annual health care costs per patient, based on the total resource consumption, were assessed from the end of treatment with DAPT to the subsequent 36-month follow-up period. Only patients still alive at the end of the follow-up period were analyzed. The total resource consumption was defined as the sum of all prescribed treatments and hospital admission. Both the overall and the CV-related annualized health care resource costs were estimated. Hospitalizations inherent to CV were identified by ICD-9-CM codes: 410, 411, 413, 433, 434, 435, 436; while the treatments of interest were antithrombotic agents (ATC code: B01) and CV (ATC code: C). Cost analysis was conducted with the perspective of the Italian National Health Service (NHS). The costs are reported in Euros (€). Drug costs were evaluated using the Italian NHS purchase price. Hospitalization costs were determined using the diagnosis-related group (DRG) tariff.
statistical analysis
Continuous variables are given as means with standard deviations (mean±SD), whereas categorical variables are shown as percentages and absolute numbers.
Cumulative incidence of CV death, composite CV endpoint, and incidence of AMI were examined using the Kaplan-Meier approach. For the composite CV endpoint, the following ICD-9-CM codes were considered: 410 (AMI), 411 (other acute and subacute forms of ischemic heart disease), 413 (angina pectoris), 433 (occlusion and stenosis of precerebral arteries), 434 (occlusion of cerebral arteries), 435 (transient cerebral ischemia), and 436 (acute, but illdefined, cerebrovascular disease). In addition, the events that occurred within 30 days were excluded. A generalized regression model was performed to identify the associations between total health care costs (in terms of drugs and hospitalizations) during the follow-up period and demographic characteristics; other guidelines recommended post-AMI therapies (including beta-blocking agents, ACE inhibitors/ AAIIs, and statin), AMI front/front-lateral at ID, previous hospitalizations for CV disorders, previous hospitalizations for heart failure, hospitalizations for neoplasia and blood transfusion, and antidiabetic, antihypertensive, or cardiac therapy required during the follow-up period. All analyses were performed with Stata software version 12.1 (StataCorp LP, College Station, TX, USA).
Results
The details of the study's inclusion and exclusion criteria are shown in Figure 1 . A total of 2,721 patients met the inclusion criteria and were considered for the analysis (Figure 1 ). Of these patients, 67.8% were males. The mean (SD) patient age at ID was 63.6 years (±17. Table 1 . An anterior/ anterolateral AMI was found in 27.6% of patients. Coronary angiography and PCI were performed in 60.8% and 67.5% of patients, respectively (Table 1) . No patients treated with DAPT underwent DES at baseline. Less than 10% of patients (n=267) had been previously hospitalized for CV disorders (Table 1) .
Patients' characteristics and health care resource utilization during the follow-up period are shown in Table 2 . Among Notes: *at least one prescription of asa and at least one prescription of P2Y12 in the month following hospital discharge; included patients (patients exposed to a period of treatment with DaPT after aMi discharge of 12 months) = 4,195, excluding lHUs of Frosinone and grosseto because data on deaths were not available (study population n=2,721). Patients with anemia or cancer were excluded. Patients with a follow-up length less than 3 years were excluded. DaPT=asa+P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor, ticlopidine). Abbreviations: AMI, acute myocardial infarction; DAPT, dual antiplatelet therapy; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; lHU, local health units.
All beneficiaries of each LHU hospitalized with a primary diagnosis of AMI (ICD-9-CM code: 410) and discharged alive between January 1, 2010 and December 31, 2011 (enrollment period). N=11,101
Patients on DAPT at discharge* N=6,706
Patients exposed to a period of treatment with DAPT after AMI discharge of 12 months N=4,195
Included patients N=2,721
Cancer at discharge N=27 
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all-cause mortality and cV events after 12 months of DaPT the enrolled patients at follow-up, 56.4% had a diagnosis of systemic arterial hypertension, 45.0% heart disease, 27.0% diabetes, 7.7% cancer, and 6.7% required blood transfusion. Statins, ACE inhibitors, and beta-blocking agents were used in 91.3%, 83.5%, and 81.9% of patients, respectively.
Of the 2,721 patients with AMI and after a 12-month treatment period with DAPT, 489 patients (18% of all patients) died within 36 months of follow-up (n=330 for the first year, n=114 and n=45 during the second and third years of followup, respectively). Figure 2 To account for all health care costs that occurred during the 36-month follow-up period, only patients still alive at the end of the follow-up period were analyzed (N=2,594 Figure 3) .
During the 36-month follow-up period, 63 patients had (at least) a second AMI event. The average cost of health care per patient during the 3-year follow-up period was €19,570.70 (of which €3,584.01 and €15,986.68 were attributable to drug treatments and hospitalization, respectively) ( Table 3) . The annual average cost per patient for these was €6,523.57, of which €1,194.67 was for drugs (particularly, €669.64 for therapies related to AMI: antithrombotic agents, ATC code: B01 and cardiovascular, ATC code: C) and €5,328.89 for hospitalizations (particularly, €3,084.14 in relation to CV hospitalizations and €2,646.31 in relation to AMI hospitalizations) (Figure 4) . The generalized regression model showed that a statistically significant increase in overall cost was caused by previous cardiovascular hospitalizations (+€6,098, P<0.01) 
Discussion
The results of this observational study suggest that among Italian patients who survived their hospitalization for an AMI and after a 12-month treatment period with DAPT, about 17% of all patients had CV events within 36 months and about 18% in the overall cohort died during the years under study. Over the past decades, medical advancements in the management of patients with AMI led to improved survival and increased life expectancy. In this regard, the incidence of AMI has declined in Western countries and 1-year post-AMI survival rates have improved, leading to growth of the stable post-MI patient population. 23 This trend has been matched 
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Degli esposti et al by a growing need to better manage patients' postdischarge and chronic care after an AMI. In line with previous studies, our results in the real-life setting showed that patients with AMI had an average age above 63 years and were predominantly male. Patients who underwent coronary angiography and PCI at the time of admission for AMI were more than half of all enrolled patients. In addition, we identified many demographic and clinical factors associated with an increased death during the 3 years after hospital discharge for AMI and after a 12-month treatment period with DAPT. Indeed, we observed that male patients and patients who were hospitalized for cancer and patients who required a blood transfusion during the follow-up period were significantly associated with an increased risk of mortality during the 3-year post-AMI from the end of treatment with DAPT.
Pivotal studies led to guidelines recommending DAPT for up to 12 months post-ACS. 24 However, the optimal duration of DAPT in post-AMI patients remains uncertain yet. 25 Indeed, despite improved secondary prevention efforts, several prior studies have shown that stable patients with a history of prior AMI are at high risk of major adverse CV events. 15, 25, 26 In other words, after AMI, patients may have a persistent state that predisposes them to benefit more from DAPT.
Recently, results of randomized clinical trials have evaluated the potential benefits of long-term DAPT. 27, 28 These data suggested that prolonged DAPT may reduce major adverse cardiac events in a population considered at high risk of antithrombotic events with prior history of AMI. 15, 25, [29] [30] [31] [32] [33] [34] This is crucial in the context where the reduction of hospital readmissions is a health priority to improve the quality of patient care and lower health care burden. 15, 35, 36 It should be highlighted that high rates of hospital readmissions indicate potentially poor health care quality or inadequate management of postdischarge care. This represents a significant burden to both patients and the health care system by imposing a significant burden in terms of morbidity and mortality and generating major public health service costs.
This retrospective analysis also underscores that over a 36-month follow-up period, health care costs (in particular hospitalization costs), especially for those patients with at least a second AMI, are relevant in the real-life setting. Few data regarding long-term CV outcomes post-AMI and related health care cost of patients are currently available. Kern et al have shown that the high risk of AMI survivors who have been event free for ≥1 year remained at substantial risk of CV events and had increased health care costs for up to 5 years post-AMI. 37 An Italian real-world study, performed in 2008, showed that direct health care costs were at least 50% higher in patients with a recurrent ACS compared with patients without recurrent ACS. 38 In particular, Roggeri et al 38 showed that, in an Italian health care setting, the average yearly costs per patient alive at the end of the follow-up period and in treatment with DAPT were €20,554 in the group of patients with recurrent ACS and €13,303 in the group of patients without recurrent ACS, respectively.
Despite the advances in medical care following AMI, readmission risk has not declined. Given the potential impact on patients' quality of life and health care costs, comprehensive strategies in care of patients with AMI including an optimization of risk stratification as well as novel therapeutic strategies are needed to prevent both the frequency and the adverse impact of future hospitalizations in the post-AMI period.
Our cohort of patients reflected real clinical practice, and the results must be interpreted taking into account limitations related to the observational nature of the study, based on data collected through administrative databases. Because the information concerning the severity of the pathology or the information related to the exact cause of death and rehospitalization were not available from the data set given their administrative scope, the results and conclusions of this study are limited to the analyzed population.
Conclusions
In a real-world setting in Italy, considering a 36-month follow-up period, all-cause mortality, CV events, and related health care cost (in particular hospitalizations costs) in patients hospitalized with the diagnosis of AMI undergoing a 12-month treatment period with DAPT remained relevant. This study suggests that increased efforts aimed at the prevention of recurrent AMI are warranted, as well as an accurate risk stratification in order to improve longterm outcome.
